Ovarian cancer stem cells and methods of isolation and uses thereof

Patent metadata

Field	Value
Publication number	US-9791449-B2
Application number	US-201214123551-A
Country	US
Kind code	B2
Filing date	Jun 1, 2012
Priority date	Jun 3, 2011
Publication date	Oct 17, 2017
Grant date	Oct 17, 2017

Abstract

The present invention generally relates to methods, assays, compositions and kits related to a subpopulation of ovarian cancer stem cells which are selected or enriched by chemotherapeutic agents and inhibited by MIS (Mullerian Inhibiting Substance) and MIS mimetics. In particular, the present invention relates to a population of CD44+/CD24+/EpCam+/ECad− subpopulation of ovarian cancer stem cells. The present invention also provides methods to screen a subject with ovarian cancer to identify if they have an ovarian cancer comprising CD44+/CD24+/EpCam+/ECad− ovarian cancer stem cells, and methods to identify and enrich or isolate for such ovarian cancer cell populations.

First claim

The invention claimed is:

1. A method to detect the presence of ovarian cancer stem cells in a population of ovarian cancer cells, the method comprising;
(a) contacting the population of ovarian cancer cells with an anti-CD24 antibody, an anti-CD44 antibody, an anti-EpCam antibody and an anti-E-Cadherin antibody; and
(b) detecting whether an ovarian cancer cell is positive for the expression of CD24, CD44, EpCam and negative for the expression of E-Cadherin by detecting positive binding between; CD24 and the anti-CD24 antibody, CD44 and the anti-CD44 antibody, EpCam and the anti-EpCam antibody and detecting negative binding between E-Cadherin and the anti-E-Cadherin antibody,
wherein the detected ovarian cancer stem cells that are positive for the expression of CD24, CD44, EpCam and negative for the expression of E-Cadherin are responsive to inhibition of proliferation by MIS.

2. The method of claim 1 , wherein the ovarian cancer stem cells are resistant to chemotherapeutic agents.

3. The method of claim 2 , wherein the chemotherapeutic agent is selected from the group consisting of: dexorubicin, taxol, cisplatin, paclitaxel and derivatives thereof.

4. The method of claim 1 , wherein the population of ovarian cancer cells is present in a biological sample, wherein the biological sample comprises any of the group consisting of: ovarian cells, ascites, ovarian cell line, ovarian cancer biopsy sample.

5. A method of diagnosing and treating a subject with ovarian cancer comprising ovarian cancer stem cells, the method comprising:
(a) contacting a population of ovarian cancer cells obtained from the subject with an anti-CD24 antibody, an anti-CD44 antibody, an anti-EpCam antibody and an anti-E-Cadherin antibody; and
(b) detecting whether an ovarian cancer stem cell is present in the population of ovarian cancer cells, by detecting whether an ovarian cancer cell is positive for the expression of CD24, CD44, EpCam and negative for the expression of E-Cadherin by detecting positive binding between; CD24 and the anti-CD24 antibody, CD44 and the anti-CD44 antibody, EpCam and the anti-EpCam antibody and detecting negative binding between E-Cadherin and the anti-E-Cadherin antibody;
(c) diagnosing the subject with ovarian cancer comprising ovarian cancer stem cells when an ovarian cancer cell positive for the expression of CD24, CD44, EpCam and negative for the expression of E-Cadherin is detected; and
(d) administering a pharmaceutically effective amount of MIS or a MIS mimetic to the diagnosed subject.

6. The method of claim 5 , wherein the MIS is recombinant human MIS (rhMIS) polypeptide or a pro-hormone or homodimer thereof.

Assignees

• Donahoe Patricia K
• Maclaughlin David T
• Teixeira Jose
• Massachusetts Gen Hospital

Inventors

• Donahoe Patricia K
• Maclaughlin David T
• Teixeira Jose

Classifications

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N2333/70585

  CD44 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/5073

  Stem cells · CPC title

• G01N2333/70596

  Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705 · CPC title